Noxopharm has replied to the USPTO requirement to refine their patent applicationIMPROVEMENTS IN CANCER TREATMENT by defining Idronoxil as their 'elected species'.
Any claims for other species that were withdrawn can be pursued in subsequent applications.
Moving forward, as expected. Harvett will no doubt take exception, but who cares?
- Forums
- ASX - By Stock
- Patent Update
NOX
noxopharm limited
Add to My Watchlist
3.06%
!
9.5¢

Noxopharm has replied to the USPTO requirement to refine their...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
9.5¢ |
Change
-0.003(3.06%) |
Mkt cap ! $27.76M |
Open | High | Low | Value | Volume |
9.5¢ | 9.5¢ | 9.5¢ | $570 | 6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 77757 | 9.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.8¢ | 8403 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 77757 | 0.093 |
2 | 17198 | 0.092 |
1 | 10989 | 0.091 |
2 | 60888 | 0.090 |
1 | 20000 | 0.080 |
Price($) | Vol. | No. |
---|---|---|
0.098 | 8403 | 1 |
0.099 | 90000 | 1 |
0.100 | 47999 | 2 |
0.105 | 31954 | 1 |
0.110 | 89079 | 5 |
Last trade - 13.55pm 15/09/2025 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
3DA
AMAERO LTD
Hank Holland, Chairman and CEO
Hank Holland
Chairman and CEO
Previous Video
Next Video
SPONSORED BY The Market Online